BernsteinのVRTX担当アナリストのVincent Chen氏が目標株価$275でカバレッジ。
Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says
Sat, November 21, 2020, 12:45
[...]
The failure of alpha-1 antitrypsin deficiency, or AATD, drug VX-814 that was subsequently discontinued has more to do with idiosyncratic toxicity, likely specific to the molecule, Chen said, citing experts in AATD.
VX-864 is a separate shot on goal, he added.
"We believe the odds of success are not as dismal as investors believe, we see near term catalysts that have potential to drive upside for the stock, and take a positive view on the stock," the analyst concluded.
BernsteinのVRTX担当アナリストのVincent Chen氏が目標株価$275でカバレッジ。
Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says
Sat, November 21, 2020, 12:45
[...]
The failure of alpha-1 antitrypsin deficiency, or AATD, drug VX-814 that was subsequently discontinued has more to do with idiosyncratic toxicity, likely specific to the molecule, Chen said, citing experts in AATD.
VX-864 is a separate shot on goal, he added.
"We believe the odds of success are not as dismal as investors believe, we see near term catalysts that have potential to drive upside for the stock, and take a positive view on the stock," the analyst concluded.